<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
2007 · Science · 4,427 citations
https://doi.org/10.1126/science.1141478
P
Pasi A. Jänne
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
2.3K
Papers
125.6K
Citations
163
h-index
575
i10-index
Pasi A. Jänne is an academic researcher from Harvard University. The author has contributed to research in topics: Lung Cancer Treatments and Mutations & Cancer Genomics and Diagnostics & Colorectal Cancer Treatments and Studies. The author has an h-index of 163, co-authored 1988 publications.
ORCID: 0000-0002-7821-4928Papers by this author
worksAdaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints
2016 · Nature Communications · 1,522 citations
https://doi.org/10.1038/ncomms10501
The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients
2019 · Cancer Discovery · 1,249 citations
https://doi.org/10.1158/2159-8290.cd-19-1167
LKB1 modulates lung cancer differentiation and metastasis
2007 · Nature · 1,060 citations
https://doi.org/10.1038/nature06030
Trastuzumab Deruxtecan in <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
2021 · New England Journal of Medicine · 911 citations
https://doi.org/10.1056/nejmoa2112431
Adagrasib in Non–Small-Cell Lung Cancer Harboring a <i> KRAS <sup>G12C</sup> </i> Mutation
2022 · New England Journal of Medicine · 886 citations
https://doi.org/10.1056/nejmoa2204619
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat